C
CureVac NV D
D
CVAC
5.43500
USD
-0.07
(-1.18%)
مغلق
حجم التداول
114,026
الربح لكل سهم
-0
العائد الربحي
-
P/E
6
حجم السوق
1,223,741,132
الأخبار المقالات
العنوان: CureVac NV
القطاع: Healthcare
الصناعة: Biotechnology
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.